Patients with obesity or overweight and T2D saw substantially greater mean weight loss and HbA1c improvement with petrelintide versus placebo.
News|Podcasts|December 4, 2025
Diabetes Dialogue: Celebrating 2025 as The Year of the Incretin Therapy
Fact checked by: Ryan Livingston, Patrick Campbell
This special edition episode explores the advancements in incretin therapies that defined 2025.
Advertisement
Advertisement
Related to this article
Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 3 months.
Presented at EASD 2026, the present analysis discusses CBL-514’s apparent efficacy in reducing L2-L3 visceral fat compared to placebo.
FDA novel drug approvals in Q3 2026: 22 new therapies, including enlicitide, daraxonrasib, oveporexton, and first treatments for rare diseases.
Remibrutinib doubled complete Total Fric Score response vs placebo at week 12 in RemIND, becoming the first therapy approved specifically for SD.
A hepatologist on the lag between drinking and liver disease, metabolic risk, prevention gaps, and when the burden may peak.
Nephrology in Q3 2026: FDA approvals for atacicept, iptacopan, finerenone, and obinutuzumab, plus 2-year IgAN data and CKD screening.
Q3 2026 dermatology recap: FDA approvals in dermatomyositis, adolescent alopecia areata, and sBCC, plus new psoriasis and vitiligo findings.
Advertisement
Advertisement